Equities

Equasens SA

Equasens SA

Actions
TechnologyTechnology
  • Price (EUR)52.40
  • Today's Change-1.00 / -1.87%
  • Shares traded6.82k
  • 1 Year change-27.42%
  • Beta0.7053
Data delayed at least 15 minutes, as of Oct 07 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Equasens SA is formerly known as Pharmagest Interactive SA is a France-based company. The Company is engaged in publishing and integration of software packages intended for pharmacies, hospitals, health establishments, laboratories, retirement homes and health professionals. Its activity is distributed in publishing and integration of software packages for pharmacies, publishing of IT solutions for health and medico-social establishments and development of solutions and infrastructure for e-Health. It provides software packages for managing databases, information, stocks, orders, electronic care sheets, etc. It offers publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, invoicing, tracking collections and accounting, care monitoring, stewardship management, etc.);

  • Revenue in EUR (TTM)219.79m
  • Net income in EUR47.05m
  • Incorporated1996
  • Employees1.24k
  • Location
    Equasens SA5 Allee de Saint-CloudVILLERS LES NANCY 54600FranceFRA
  • Phone+33 383159595
  • Fax+33 383159805
  • Websitehttps://equasens.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EQS:PAR since
announced
Transaction
value
SARL DigipharmacieAnnounced02 Jan 202402 Jan 2024Announced-14.24%--
Data delayed at least 15 minutes, as of Oct 07 2024 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SQLI SA249.30m4.55m252.06m2.06k56.201.8815.691.010.96084.5852.7928.700.9533--3.33117,817.101.741.782.572.7999.4199.341.821.93--4.130.314113.112.171.60-37.469.45-2.45--
Infotel SA307.55m18.07m303.74m1.96k16.692.5610.770.98762.622.6244.6517.101.19--4.21157,152.307.186.6412.5011.9499.9399.906.025.68----0.214975.682.375.83-11.033.68-1.784.56
Sword Group SE298.89m20.11m346.01m2.23k17.033.6812.031.162.132.1331.629.841.150.49488.74134,940.407.9017.8112.4025.4990.3892.566.8818.130.986612.440.391888.495.8310.95-79.21-22.48-16.987.21
Quadient SA1.07bn71.80m550.12m4.72k7.610.51573.200.51212.101.6631.4430.950.4113.345.49227,536.502.771.683.802.1774.2573.216.754.550.85034.080.463743.82-0.8123-0.5463724.00-0.04852.864.17
Aubay SA531.61m33.30m567.00m7.55k16.852.1214.761.072.582.5841.1220.451.16174.773.2468,338.607.257.7711.6113.0875.0078.296.266.611.73--0.07337.234.015.92-6.234.10-2.8414.87
Equasens SA219.79m47.05m810.30m1.24k17.223.6613.303.693.103.1014.4814.590.59027.054.42177,248.4012.8112.8718.2418.3668.5468.6921.7120.761.13--0.227342.222.678.161.7313.0910.718.02
Neurones SA774.91m48.49m1.08bn6.85k22.283.0814.461.391.991.9931.8514.411.190.43024.62114,819.108.887.9615.3613.0599.9199.917.467.402.24--0.104869.0411.398.6311.6813.7420.9482.06
Lectra SA500.31m31.94m1.09bn2.95k34.383.5316.662.180.83760.837613.128.170.5892.005.55196,200.403.515.285.217.7370.9869.625.977.960.65798.870.3145.91-8.5011.07-23.623.36-11.03-2.09
Ovh Groupe SA944.05m-30.98m1.27bn2.92k--3.204.051.34-0.1608-0.16084.902.080.5931--23.46327,453.00-1.95-2.42-2.54-3.2878.4878.30-3.28-4.00--0.22040.6807--13.8711.89-41.21--3.23--
Wavestone SA701.06m58.20m1.37bn4.48k20.552.3819.451.962.692.6932.6923.160.9258--3.32156,520.707.748.2911.1312.5690.3394.988.368.50--44.550.128515.6131.7112.3616.2413.5916.5010.56
Exclusive Networks SAS1.51bn41.00m2.16bn2.71k52.362.1918.941.430.44970.449716.5310.760.47635.031.39591,516.101.300.41142.360.674132.6715.722.720.52191.044.070.3696---54.20--19.44------
Alten SA4.13bn240.31m3.40bn58.30k13.931.5810.000.82336.936.93119.0961.201.19--3.1072,437.376.939.0510.4913.9889.2089.535.817.32----0.145815.807.5512.38-49.038.124.348.45
Sopra Steria Group SA5.91bn240.50m3.97bn56.00k16.521.998.840.671511.709.45287.2096.960.9929--4.31105,933.804.003.887.606.6975.5280.744.033.81--13.800.452231.9013.807.23-25.877.9910.2020.24
Data as of Oct 07 2024. Currency figures normalised to Equasens SA's reporting currency: Euro EUR

Institutional shareholders

9.20%Per cent of shares held by top holders
HolderShares% Held
Amundi Asset Management SA (Investment Management)as of 03 Jul 2024260.12k1.71%
The Vanguard Group, Inc.as of 04 Jul 2024165.48k1.09%
DNCA Finance SAas of 29 Dec 2023159.95k1.05%
Comgest SAas of 30 Apr 2024143.39k0.95%
Danske Bank A/S (Investment Management)as of 31 Jul 2024138.87k0.92%
Swedbank Robur Fonder ABas of 28 Jun 2024136.00k0.90%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 May 2023110.03k0.73%
Cr�dit Mutuel Asset Management SAas of 30 Jun 202397.90k0.65%
Capricorn Venture Partners NV (Investment Management)as of 30 Jun 202492.76k0.61%
Amplegest SASas of 31 Aug 202390.84k0.60%
More ▼
Data from 28 Feb 2024 - 07 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.